title: [Misoprostol for treating postpartum hemorrhages].
abstract: Postpartum hemorrhage is defined by bleeding > 500 mL through the vagina. It is one of the obstetrical complications that obstetricians fear most. It is the leading cause of maternal mortality in the world, especially in developing countries. The reference treatments in France are parenteral oxytocin and sulprostone. Sulprostone involves sometimes fatal side effects, and must be administered only in appropriate health care facilities. It also has the major disadvantage of requiring refrigeration. Misoprostol has uterotonic properties that have led to its occasional off-label use in the treatment of postpartum hemorrhage, by rectal or sublingual administration, as an alternative to sulprostone. A careful review of the literature on this particular use of misoprostol is essential.
authors.affiliation: Service de pharmacie et toxicologie, Centre hospitalier universitaire Jean Verdier, Bondy (93).
authors.forename: Clémence
authors.initials: C
authors.lastname: Godard
authors.forename: Malik
authors.initials: M
authors.lastname: Berhoune
authors.forename: Eric
authors.initials: E
authors.lastname: Bertrand
authors.forename: Joël
authors.initials: J
authors.lastname: Schlatter
authors.forename: Fouad
authors.initials: F
authors.lastname: Chiadmi
authors.forename: Audrey
authors.initials: A
authors.lastname: Toledano
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cisternino
authors.forename: Jean-Eudes
authors.initials: JE
authors.lastname: Fontan
mesh_terms: D005260:Female; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use*; D006473:Postpartum Hemorrhage / Q000188:drug therapy*; D011247:Pregnancy
chemical_list: D016595:Misoprostol